MGX
Metagenomi, Inc. Common Stock
NASDAQ · Healthcare · Biotechnology · US
$1.17
+0.86%Aug 10, 2026, 22:56 UTC
Metagenomi Therapeutics reported a Q2 2026 loss of $0.73 per share, missing the Zacks Consensus Estimate of a $0.63 loss and wider than the year-ago loss of $0.54 per share.
Source:Jun 10, 2026, 00:00 UTC
Brian C. Thomas, Ph.D. resigned as a member of the Board of Metagenomi Therapeutics, Inc., effective June 9, 2026.